Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics, Inc. (CADL) furnished an investor presentation outlining clinical, commercial and financial updates across its oncology pipeline. Lead asset aglatimagene besadenovec (CAN-2409) achieved the primary endpoint in a randomized phase 3 trial in intermediate- to high-risk localized prostate cancer, delivering a 30% reduction in risk of disease-free survival events versus placebo plus standard of care (hazard ratio 0.70; P=0.0155) in 745 patients and a 38% reduction in prostate cancer-specific disease-free survival events (hazard ratio 0.62; P=0.0046).
The presentation reports supportive secondary outcomes, including higher pathological complete response rates on 2‑year biopsies (80% vs 63%) and more patients reaching PSA nadir <0.2 ng/mL (67.1% vs 58.6%). In PD‑1–refractory non-small cell lung cancer, phase 2a aglatimagene data show median overall survival up to 25.4 months, compared with historical chemotherapy benchmarks cited in the deck. Second program linoserpaturev (CAN‑3110) in recurrent high‑grade glioma shows median overall survival of about 11–12 months in early studies, versus historical 6–9 months referenced.
Financially, Candel highlights a term loan facility of up to $130 million, a $100 million royalty funding agreement contingent on prostate cancer approval, and $201.6 million of cash and cash equivalents as of June 30, 2026, which it states is expected to fund operations into the first quarter of 2028. The company also notes ongoing pre-commercialization efforts for a potential U.S. launch of aglatimagene in prostate cancer and states that a BLA filing is expected in the fourth quarter of 2026.
Candel Therapeutics, Inc. (CADL) reported that Chief Technology Officer Tyagarajan Seshu sold 7,000 shares of common stock at $12.00 per share on 2026-08-17 in an open-market or private transaction. Following this sale, Seshu directly held 76,865 shares of Candel Therapeutics common stock. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on 3/16/2026.
CADL reporting person Seshu P. Tyagarajan filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC, with the shares listed on NASDAQ. The shares relate to Restricted Stock Units granted on 01/07/2025 and are associated with Rule 10b5-1 sales dated 06/29/2026, with disclosed transaction values of $82,040.00 and $70,151.20.
Candel Therapeutics, Inc. reported substantially higher operating investment and losses for the three and six months ended June 30, 2026, while significantly strengthening its balance sheet. Total assets were $208.1 million, driven largely by cash and cash equivalents of $201.6 million, up from $119.7 million at year-end after a $100 million follow-on equity offering (net proceeds $93.5 million) and $24.2 million raised through at-the-market sales.
Operating expenses more than doubled year over year, with research and development of $19.8 million and general and administrative of $6.9 million in the quarter, leading to a Q2 2026 net loss of $38.9 million versus a $4.8 million loss a year earlier. For the first half, the company posted a net loss of $47.8 million versus $2.6 million of net income in 2025, reflecting increased clinical spend, higher commercial readiness costs, and a non-cash loss from remeasuring warrant liabilities. Net cash used in operating activities was $35.2 million in the first half. Candel also has a $50 million Trinity Capital term loan outstanding and believes its current resources will fund planned operations for at least 12 months. The company continues to advance aglatimagene and linoserpaturev through clinical trials, supported by an RTW royalty-based funding agreement contingent on future FDA approval of aglatimagene.
Candel Therapeutics reported second-quarter 2026 results and progress across its oncology pipeline. The company is planning a Biologics License Application in Q4 2026 for aglatimagene besadenovec in localized, intermediate- to high-risk prostate cancer, supported by pivotal phase 3 data published in The Lancet Oncology showing improved disease-free survival versus radiotherapy alone. A global pivotal phase 3 AURORA trial in metastatic non-squamous NSCLC has opened enrollment, and development planning continues for linoserpaturev in recurrent glioblastoma.
Research and development expenses rose to $19.8 million from $7.0 million, and general and administrative expenses to $6.9 million from $4.2 million, driving a wider net loss of $38.9 million versus $4.8 million a year earlier, largely due to warrant liability remeasurement. Cash and cash equivalents were $201.6 million at June 30, 2026, up from $119.7 million at December 31, 2025, which the company expects will fund its operating plan into Q1 2028, including preparations for a potential U.S. commercial launch of aglatimagene in 2027 if approved.
BlackRock, Inc. reported a passive ownership position in Candel Therapeutics, Inc. common stock on a Schedule 13G. BlackRock disclosed beneficial ownership of 4,834,899 shares of common stock, representing 6.6% of Candel Therapeutics’ outstanding common shares.
BlackRock reported sole voting power over 4,763,922 shares and sole dispositive power over 4,834,899 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Candel’s outstanding common shares.
Candel Therapeutics Chief Commercial Officer Mark E. Sims received a grant of stock options covering 285,000 shares of common stock. The options have an exercise price of $10.03 per share and expire on July 6, 2036. Twenty-five percent vest on July 6, 2027, with the remainder vesting in 36 equal monthly installments, contingent on continued service.
Candel Therapeutics, Inc. filed a Form 3 identifying Mark E. Sims as an officer of the company, serving as Chief Commercial Officer. The filing does not report any share transactions or holdings for Sims, and the transaction summary shows no purchases, sales, exercises, gifts, or other movements.
Candel Therapeutics Chief Scientific Officer Francesca Barone sold 23,447 shares of common stock in an open-market transaction at a weighted average price of $10.0554 per share on June 29, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted on March 16, 2026, and Barone now directly holds 77,362 shares.
Candel Therapeutics, Inc. Chief Technology Officer Tyagarajan Seshu reported an open-market sale of 7,000 shares of common stock at a weighted average price of $10.0216 per share on June 29, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 16, 2026.
After this transaction, Seshu directly holds 83,865 shares of Candel Therapeutics common stock. The price reflected a range of individual trades between $10.00 and $10.07 per share.